Conclusions
DISEASE
Anlotinib as a third- or later-line treatment is well tolerated and has demonstrated promising anti-tumor activity and disease control in heavily pretreated RM-NPC patients. The efficacy and safety of anlotinib in combination with immune checkpoint inhibitors for the treatment of RM-NPC patients should be further explored.